Does Dupilumab Sustain Oral Corticosteroid (OCS) Reduction in Patients With Corticosteroid-Dependent Asthma? (TRAVERSE Study)

**STUDY DESIGN**
Multicenter, single-arm, open-label extension study of patients who had been previously randomized (as part of VENTURE study) to receive dupilumab vs placebo for 24 weeks

All patients received dupilumab.

Compared:
PLACEBO/DUILUMAB (PBO/DPL) (N=97)

**RESULTS**
At 96 weeks, OCS dose decreased by ↓89.3% in dupilumab/dupilumab group and by ↓74.4% in placebo/dupilumab group

In the TRAVERSE study, dupilumab sustained the oral corticosteroid dose reduction seen in the shorter term study, VENTURE, for at least 96 weeks and also maintained low exacerbation rate and improved lung function.

Sher LD, et al. CHEST July 2022 | @journal_CHEST | https://doi.org/10.1016/j.chest.2022.02.025
Copyright © 2022 American College of Chest Physicians